Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2227-2232

  Obata, Hiroaki ^a   Yahata, Tetsuro ^a   Quan, Jinhua ^a   Sekine, Masayuki ^a   Tanaka, Kenichi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Chemotherapy; Drug resistance gene; MRP1; Ovarian cancer; SNP

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MARKER; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PLATINUM; TAXANE DERIVATIVE;

ADVANCED CANCER; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; JAPAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS (GENETICS); TAXOIDS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 33745535229     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ozols RF: Treatment of ovarian cancer: Current status. Semin Oncol 21: 1-9, 1994.
2. Arts HJ, Katsaros D, de Vries EG et al: Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5: 2798-2805, 1999.
3. Leonard GD, Polgar O and Bates SE: ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3: 1652-1659, 2002.
4. Hou YX, Cui L, Riordan JR et al: ATP binding to the first nucleotide-binding domain of multidrug resistance protein MRP1 increases binding and hydrolysis of ATP and trapping of ADP at the second domain. J Biol Chem 277: 5110-5119, 2002.
5. Brant SR, Panhuysen CI, Nicolae D et al: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 73: 1282-1292, 2003.
6. Damiani D, Michieli M, Michelutti A et al: Antibody binding capacity for evaluation of MDR-related proteins in acute promyelocytic leukemia: onset versus relapse expression. Cytometry B Clin Cytom 59: 40-45, 2004.
7. Efferth T, Sauerbrey A, Steinbach D et al: Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol 23: 509-517, 2003.
8. Yusuf RZ, Duan Z, Lamendola DE et al: Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3: 1-19, 2003.
9. Yamamoto K, Kikuchi Y, Kudoh K et al: Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 126: 168-172, 2000.
10. Shirakawa K, Takara K, Tanigawara Y et al: Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res 90: 1380-1386, 1999.
11. Schondorf T, Neumann R, Benz C et al: Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Rec Results Cancer Res 161: 111-116, 2003.
12. Kamazawa S, Kigawa J, Kanamori Y et al: Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86: 171-176, 2002.
13. Itoh Y, Tamai M, Yokogawa K et al: Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells. Anticancer Res 22: 1649-1653, 2002.
14. Suzuki T, Nishio K and Tanabe S: The MRP family and anticancer drug metabolism. Curr Drug Metab 2: 367-377, 2001.
15. Izquierdo MA, van der Zee AG, Vermorken JB et al: Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87: 1230-1237, 1995.
16. Kuttesch JF, Parham DM, Luo X et al: P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 14: 886-900, 1996.
17. Scheper RJ, Broxterman HJ, Scheffer GL et al: Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479, 1993.
18. Komdeur R, Plaat BE, Hoekstra HJ et al: Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 91: 1940-1948, 2001.
19. Hirakawa M, Tanaka T, Hashimoto Y et al: JSNP: a database of common gene variations in the Japanese population. Nucleic Acids Res 30: 158-162, 2002.
20. Ito S, Ieiri I, Tanabe M et al: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11: 175-184, 2001.
21. Kerb R, Hoffmeyer S and Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2: 51-64, 2001.
22. Savaraj N, Wu CJ, Xu R et al: Multidrug-resistant gene expression in small-cell lung cancer. Am J Clin Oncol 20: 398-403, 1997.
23. Illmer T, Schuler US, Thiede C et al: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62: 4955-4962, 2002.
24. Yokoyama Y, Sato S, Fukushi Y et al: Significance of multidrug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25: 387-394, 1999.
25. Ameyaw MM, Regateiro F, Li T et al: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11: 217-221, 2001.
26. Materna V, Pleger J, Hoffmann U et al: RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94: 152-160, 2004.
27. Ohishi Y, Oda Y, Uchiumi T et al: ATP-binding cassette superfamily transporter gène expression in human primary ovarian carcinoma. Clin Cancer Res 8: 3767-3775, 2002.
28. Schneider J, Gonzalez-Roces S, Pollan M et al: Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res 3: 183-191, 2001.
29. Filipits M, Drach J, Pohl G et al: Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 5: 2426-2430, 1999.
30. Hoffmeyer S, Burk O, von Richter O et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478, 2000.
31. Humeny A, Rodel F, Rodel C et al: MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. Anticancer Res 23: 2735-2740, 2003.
32. Kafka A, Sauer G, Jaeger C et al: Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22: 1117-1121, 2003.
33. Suzuki H and Sugiyama Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 54: 1311-1331, 2002.